Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)

Active, not recruiting

Conditions: Asthma

Interventions: Drug: Dupilumab SAR231893

First Posted Date: 2020-09-16

Last Posted Date: 2024-05-30

Lead Sponsor: Sanofi

Target Recruit Count: 375

Registration Number: NCT04550962

Locations: 🇰🇼
Investigational Site Number : 4140001, Kuwait, Kuwait
🇦🇷
Investigational Site Number : 0320004, Santa Fe, Argentina
🇨🇴
Investigational Site Number : 1700009, Barranquilla, Colombia

and more 38 locations

Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC

Phase 2

Terminated

Conditions: Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Interventions: Drug: SAR408701 (Tusamitamab ravtansine)
Drug: Pembrolizumab
Drug: Cisplatin
Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2020-08-24

Last Posted Date: 2025-03-17

Lead Sponsor: Sanofi

Target Recruit Count: 57

Registration Number: NCT04524689

Locations: 🇺🇸
KU Medical Center_Investigational Site Number :8400002, Westwood, Kansas, United States
🇧🇷
Centro Avancado de Oncologia CECAN - Liga Contra o Cancer Site Number : 0760004, Natal, Rio Grande Do Norte, Brazil
🇨🇱
Centro de Investigacion y Desarrollo Oncologico (CIDO) Hochstetter 599 of. 602-603-1001, Temuco_Investigational Site Number :1520005, Temuco, La Araucanía, Chile

and more 19 locations

First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to Overweight Subjects

Phase 1

Completed

Conditions: Overweight
Healthy Subjects

Interventions: Drug: SAR441255
Drug: placebo

First Posted Date: 2020-08-20

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 48

Registration Number: NCT04521738

Locations: 🇺🇸
Investigational site number 8400001, Knoxville, Tennessee, United States

A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: SAR231893
Drug: Placebo

First Posted Date: 2020-08-06

Last Posted Date: 2024-12-06

Lead Sponsor: Sanofi

Target Recruit Count: 202

Registration Number: NCT04502862

Locations: 🇺🇸
Todd Astor MD Site Number : 8400016, Culver City, California, United States
🇺🇸
Kern Allergy and Medical Research. Inc. Site Number : 8400003, Bakersfield, California, United States
🇺🇸
Southern California Institute for Respiratory Diseases Site Number : 8400009, Los Angeles, California, United States

and more 52 locations

Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer

Phase 3

Terminated

Conditions: Breast Cancer

Interventions: Drug: Amcenestrant-matching placebo
Drug: SAR439859
Drug: Palbociclib
Drug: Letrozole
Drug: Letrozole-matching placebo
Drug: Goserelin

First Posted Date: 2020-07-20

Last Posted Date: 2023-12-08

Lead Sponsor: Sanofi

Target Recruit Count: 1068

Registration Number: NCT04478266

Locations: 🇺🇸
Investigational Site Number :8400029, Santa Monica, California, United States
🇺🇸
Investigational Site Number :8400038, Fullerton, California, United States
🇺🇸
Investigational Site Number :8400013, Westwood, Kansas, United States

and more 246 locations

A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19

Phase 1

Completed

Conditions: Corona Virus Infection

Interventions: Drug: Placebo
Drug: SAR443122

First Posted Date: 2020-07-14

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 68

Registration Number: NCT04469621

Locations: 🇦🇷
Investigational Site Number 0320001, Caba, Argentina
🇨🇱
Investigational Site Number 1520003, Santiago, Chile
🇷🇺
Investigational Site Number 6430002, Moscow, Russian Federation

and more 7 locations

A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Active, not recruiting

Conditions: Plasma Cell Myeloma

Interventions: Drug: isatuximab SAR650984
Drug: Pomalidomide
Drug: Dexamethasone
Drug: Carfilzomib

First Posted Date: 2020-07-07

Last Posted Date: 2025-03-24

Lead Sponsor: Sanofi

Target Recruit Count: 586

Registration Number: NCT04458831

Locations: 🇩🇪
Investigational Site Number : 2760003, Berlin, Germany
🇩🇪
Investigational Site Number : 2760041, Berlin, Germany
🇫🇷
Investigational Site Number : 2500011, Vannes Cedex, France

and more 126 locations

Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

Phase 3

Active, not recruiting

Conditions: Primary Progressive Multiple Sclerosis

Interventions: Drug: Tolebrutinib
Drug: Placebo

First Posted Date: 2020-07-07

Last Posted Date: 2025-01-13

Lead Sponsor: Sanofi

Target Recruit Count: 767

Registration Number: NCT04458051

Locations: 🇺🇸
Multiple Sclerosis Center- Site Number : 8400143, Los Angeles, California, United States
🇺🇸
University of San Francisco, Sandler Neurosciences Center- Site Number : 8400137, San Francisco, California, United States
🇺🇸
Neurology Associates, PA- Site Number : 8400004, Maitland, Florida, United States

and more 274 locations

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Dupilumab SAR231893
Drug: Inhaled Corticosteroid
Drug: Inhaled Long-Acting Beta Agonist
Drug: Inhaled Long-Acting Muscarinic Antagonist
Drug: Placebo

First Posted Date: 2020-07-02

Last Posted Date: 2025-03-17

Lead Sponsor: Sanofi

Target Recruit Count: 935

Registration Number: NCT04456673

Locations: 🇺🇸
Radiance Clinical Research Site Number : 8400029, Lampasas, Texas, United States
🇺🇸
Cullman Research Center, LLC Site Number : 8400095, Cullman, Alabama, United States
🇺🇸
Pulmonary & Sleep Associates of Jasper PC Site Number : 8400090, Jasper, Alabama, United States

and more 331 locations

Dupilumab Skin Barrier Function Study in Atopic Dermatitis

Phase 4

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Dupilumab SAR231893

First Posted Date: 2020-06-25

Last Posted Date: 2022-07-22

Lead Sponsor: Sanofi

Target Recruit Count: 52

Registration Number: NCT04447417

Locations: 🇺🇸
Investigational Site Number 8400001, Denver, Colorado, United States
🇨🇦
Investigational Site Number 1240001, Montreal, Canada

Home Terms & Conditions Privacy Policy